What were Caplin Point Laboratories Ltd's latest quarterly results?
Caplin Point Laboratories Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +19.3% (stable)
- Revenue Growth YoY: +19.5%
- Operating Margin: 34.0% (expanding)
Caplin Point Laboratories Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +49.5%Average5w Streak
In , Caplin Point Laboratories Ltd (Pharma - Formulators) is outperforming Nifty 500 with +49.5% relative strength. Fundamentals: Average. On a 5-week streak.
Caplin Point Laboratories Ltd Key Facts
- PE Ratio
- 29.7x
- Market Cap
- ₹19,052 Cr
- PAT Growth YoY
- +19%
- Revenue Growth YoY
- +20%
- OPM
- 34.0%
- RS vs Nifty 500
- +49.5%
PE: Mid ExpansionStrong Opportunity
What's Happening
💎PE falling while earnings hold — value emerging
📊Debt increased 150% YoY — leverage rising
🌐FII stake increased 2.8% this quarter
💰Trading 20% below estimated fair value
Key Numbers
PAT Growth YoY
+19%
Stable
Revenue YoY
+20%
Stable
Operating Margin
34.0%
+100 bps YoY
PE Ratio
29.7
Current Price
₹2,506
Dividend Yield
0.24%
Fundamental Score
56/100
Average
3Y PAT CAGR
+20%
Market Cap
19.1K Cr
Valuation
Undervalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Caplin Point Laboratories Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +20% | +14% | Stable |
| PAT (Net Profit) | +19% | +20% | Stable |
| OPM | 34.0% | +100 bps | Expanding |
Other Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Caplin Point Laboratories Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Caplin Point Laboratories Ltd's profit growing or declining?
Caplin Point Laboratories Ltd's profit is growing with an stable trend.
- PAT Growth YoY: +19.3% (latest quarter)
- PAT Growth QoQ: +4.2% (sequential)
- 3-Year PAT CAGR: +19.9%
- Trend: Stable — consistent growth pattern
What is Caplin Point Laboratories Ltd's revenue growth trend?
Caplin Point Laboratories Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +19.5%
- Revenue Growth QoQ: +10.5% (sequential)
- 3-Year Revenue CAGR: +14.2%
How is Caplin Point Laboratories Ltd's operating margin trending?
Caplin Point Laboratories Ltd's operating margin is expanding.
- Current OPM: 34.0%
- OPM Change YoY: +1.0% basis points
- OPM Change QoQ: -1.0% basis points
What is Caplin Point Laboratories Ltd's 3-year profit and revenue CAGR?
Caplin Point Laboratories Ltd's long-term compounding rates
- 3-Year Profit CAGR: +19.9%
- 3-Year Revenue CAGR: +14.2%
Is Caplin Point Laboratories Ltd's growth accelerating or decelerating?
Caplin Point Laboratories Ltd's earnings growth is stable with positive momentum on a sequential basis.
- YoY Acceleration: +0.7% bps
- Sequential Acceleration: +0.4% bps
What is Caplin Point Laboratories Ltd's trailing twelve month (TTM) performance?
Caplin Point Laboratories Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹650 Cr
- TTM PAT Growth: +20.1% YoY
- TTM Revenue: ₹2,000 Cr
- TTM Revenue Growth: +12.9% YoY
- TTM Operating Margin: 34.7%
Is Caplin Point Laboratories Ltd overvalued or undervalued?
Caplin Point Laboratories Ltd appears undervalued based on our fair value analysis.
- Valuation Signal: Undervalued
- Current PE: 29.7x
- Price-to-Book: 5.3x
What is Caplin Point Laboratories Ltd's current PE ratio?
Caplin Point Laboratories Ltd's current PE ratio is 29.7x.
- Current PE: 29.7x
- Market Cap: 19.1K Cr
- Dividend Yield: 0.24%
How does Caplin Point Laboratories Ltd's valuation compare to its history?
Caplin Point Laboratories Ltd's current PE is 29.7x.
- Current PE: 29.7x
- Valuation Assessment: Undervalued
What is Caplin Point Laboratories Ltd's price-to-book ratio?
Caplin Point Laboratories Ltd's price-to-book ratio is 5.3x.
- Price-to-Book (P/B): 5.3x
- Book Value per Share: ₹472
- Current Price: ₹2506
Is Caplin Point Laboratories Ltd a fundamentally strong company?
Caplin Point Laboratories Ltd is rated Average with a fundamental score of 55.8/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +19.5% (10% weight)
- PAT Growth YoY: +19.3% (10% weight)
- PAT Growth QoQ: +4.2% (10% weight)
- Margins expanding (10% weight)
Is Caplin Point Laboratories Ltd debt free?
Caplin Point Laboratories Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹5 Cr
What is Caplin Point Laboratories Ltd's return on equity (ROE) and ROCE?
Caplin Point Laboratories Ltd's return ratios over recent years
- FY2024: ROCE 26.0%
- FY2025: ROCE 26.0%
- FY2026: ROCE 25.0%
Is Caplin Point Laboratories Ltd's cash flow positive?
Caplin Point Laboratories Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹523 Cr
- Free Cash Flow (FCF): ₹-59 Cr
- CFO/PAT Ratio: 80% (strong cash conversion)
What is Caplin Point Laboratories Ltd's dividend yield?
Caplin Point Laboratories Ltd's current dividend yield is 0.24%.
- Dividend Yield: 0.24%
- Current Price: ₹2506
Who holds Caplin Point Laboratories Ltd shares — promoters, FII, DII?
Caplin Point Laboratories Ltd's shareholding pattern (Mar 2026)
- Promoters: 70.6%
- FII (Foreign): 6.2%
- DII (Domestic): 2.1%
- Public: 21.1%
Is promoter holding increasing or decreasing in Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 70.6% (Mar 2026)
- Previous Quarter: 70.6% (Dec 2025)
- Change: 0.00% (stable)
How long has Caplin Point Laboratories Ltd been outperforming Nifty 500?
Caplin Point Laboratories Ltd has been outperforming Nifty 500 for 5 consecutive weeks, indicating building momentum.
Is Caplin Point Laboratories Ltd a new momentum entry or an established outperformer?
Caplin Point Laboratories Ltd is an established outperformer with 5 weeks of consecutive Nifty 500 outperformance.
Is Caplin Point Laboratories Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Caplin Point Laboratories Ltd may be worth studying
- Earnings growing at +19.3% YoY
- Operating margins are expanding — OPM at 34.0%
- Valuation: appears undervalued
- Cash flow is positive — CFO ₹523 Cr
What is the investment thesis for Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +19.5% YoY
- Margins expanding
- Appears undervalued
What is the future outlook for Caplin Point Laboratories Ltd?
Caplin Point Laboratories Ltd's forward outlook based on current data signals
- Earnings Trend: stable
- Revenue Trend: stable
- Margin Trend: expanding
- Valuation: Undervalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.